La bourse ferme dans 3 h 45 min
  • CAC 40

    6 631,01
    -35,25 (-0,53 %)
     
  • Euro Stoxx 50

    4 126,02
    -32,12 (-0,77 %)
     
  • Dow Jones

    33 823,45
    -210,22 (-0,62 %)
     
  • EUR/USD

    1,1912
    +0,0001 (+0,01 %)
     
  • Gold future

    1 792,90
    +18,10 (+1,02 %)
     
  • BTC-EUR

    31 789,69
    -1 344,38 (-4,06 %)
     
  • CMC Crypto 200

    935,92
    -33,96 (-3,50 %)
     
  • Pétrole WTI

    70,60
    -0,44 (-0,62 %)
     
  • DAX

    15 591,32
    -136,35 (-0,87 %)
     
  • FTSE 100

    7 076,06
    -77,37 (-1,08 %)
     
  • Nasdaq

    14 161,35
    +121,67 (+0,87 %)
     
  • S&P 500

    4 221,86
    -1,84 (-0,04 %)
     
  • Nikkei 225

    28 964,08
    -54,25 (-0,19 %)
     
  • HANG SENG

    28 801,27
    +242,68 (+0,85 %)
     
  • GBP/USD

    1,3885
    -0,0039 (-0,28 %)
     

Global Gene Delivery Systems Industry

·26 min de lecture

Global Gene Delivery Systems Market to Reach $4 Billion by 2027. Amid the COVID-19 crisis, the global market for Gene Delivery Systems estimated at US$2. 6 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at aCAGR of 6.

New York, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gene Delivery Systems Industry" - https://www.reportlinker.com/p05960944/?utm_source=GNW
4% over the period 2020-2027. Viral Gene Delivery, one of the segments analyzed in the report, is projected to record 6.6% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-viral Gene Delivery segment is readjusted to a revised 4.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $758.6 Million, While China is Forecast to Grow at 6% CAGR

The Gene Delivery Systems market in the U.S. is estimated at US$758.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$695.5 Million by the year 2027 trailing a CAGR of 6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.We bring years of research experience to this 8th edition of our report. The 247-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Amgen, Inc.

  • Bayer AG

  • Human Stem Cells Institute

  • Johnson & Johnson

  • Novartis AG

  • Oxford Biomedica plc

  • Pfizer, Inc.

  • Shanghai Sunway Biotech Co., Ltd.

  • Sibiono GeneTech Co. Ltd.




Read the full report: https://www.reportlinker.com/p05960944/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Gene Delivery System Competitor Market Share Scenario Worldwide
(in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Gene Delivery
Systems by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 2: World Historic Review for Gene Delivery Systems by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 3: World 15-Year Perspective for Gene Delivery Systems by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Viral Gene
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 5: World Historic Review for Viral Gene Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 6: World 15-Year Perspective for Viral Gene Delivery by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Non-viral Gene
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 8: World Historic Review for Non-viral Gene Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 9: World 15-Year Perspective for Non-viral Gene Delivery
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Infectious
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 11: World Historic Review for Infectious Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 12: World 15-Year Perspective for Infectious Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 14: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 15: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 16: World Current & Future Analysis for CVD by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027

Table 17: World Historic Review for CVD by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 18: World 15-Year Perspective for CVD by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 19: World Current & Future Analysis for Urology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 20: World Historic Review for Urology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 21: World 15-Year Perspective for Urology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 22: World Current & Future Analysis for CNS by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027

Table 23: World Historic Review for CNS by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 24: World 15-Year Perspective for CNS by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 25: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 26: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 27: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Oral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 29: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 30: World 15-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 31: World Current & Future Analysis for Injectable by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 32: World Historic Review for Injectable by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 33: World 15-Year Perspective for Injectable by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Inhalation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 35: World Historic Review for Inhalation by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 36: World 15-Year Perspective for Inhalation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Transdermal by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 38: World Historic Review for Transdermal by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 39: World 15-Year Perspective for Transdermal by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Ocular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 41: World Historic Review for Ocular by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 42: World 15-Year Perspective for Ocular by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 43: World Current & Future Analysis for Nasal by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 44: World Historic Review for Nasal by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 45: World 15-Year Perspective for Nasal by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 46: World Current & Future Analysis for Other Route of
Administrations by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 47: World Historic Review for Other Route of
Administrations by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 48: World 15-Year Perspective for Other Route of
Administrations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Gene Delivery System Market Share (in %) by Company: 2019 &
2025
Market Analytics
Table 49: USA Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 50: USA Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 51: USA 15-Year Perspective for Gene Delivery Systems by
Delivery - Percentage Breakdown of Value Sales for Viral Gene
Delivery and Non-viral Gene Delivery for the Years 2012, 2020 &
2027

Table 52: USA Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 53: USA Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 54: USA 15-Year Perspective for Gene Delivery Systems by
Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 55: USA Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 56: USA Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 57: USA 15-Year Perspective for Gene Delivery Systems by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal
and Other Route of Administrations for the Years 2012, 2020 &
2027

CANADA
Table 58: Canada Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 59: Canada Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 60: Canada 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 61: Canada Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 62: Canada Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 63: Canada 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 64: Canada Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 65: Canada Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 66: Canada 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

JAPAN
Table 67: Japan Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 68: Japan Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 69: Japan 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 70: Japan Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 71: Japan Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 72: Japan 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 73: Japan Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 74: Japan Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 75: Japan 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

CHINA
Table 76: China Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 77: China Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 78: China 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 79: China Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 80: China Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 81: China 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 82: China Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 83: China Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 84: China 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

EUROPE
Market Facts & Figures
European Gene Delivery System Market: Competitor Market Share
Scenario (in %) for 2019 & 2025
Market Analytics
Table 85: Europe Current & Future Analysis for Gene Delivery
Systems by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2020 through 2027

Table 86: Europe Historic Review for Gene Delivery Systems by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019

Table 87: Europe 15-Year Perspective for Gene Delivery Systems
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 88: Europe Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 89: Europe Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 90: Europe 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 91: Europe Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 92: Europe Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 93: Europe 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 94: Europe Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 95: Europe Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 96: Europe 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

FRANCE
Table 97: France Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 98: France Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 99: France 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 100: France Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 101: France Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 102: France 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 103: France Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 104: France Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 105: France 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

GERMANY
Table 106: Germany Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 107: Germany Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 108: Germany 15-Year Perspective for Gene Delivery
Systems by Delivery - Percentage Breakdown of Value Sales for
Viral Gene Delivery and Non-viral Gene Delivery for the Years
2012, 2020 & 2027

Table 109: Germany Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 110: Germany Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 111: Germany 15-Year Perspective for Gene Delivery
Systems by Application - Percentage Breakdown of Value Sales
for Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 112: Germany Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 113: Germany Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 114: Germany 15-Year Perspective for Gene Delivery
Systems by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Injectable, Inhalation, Transdermal,
Ocular, Nasal and Other Route of Administrations for the Years
2012, 2020 & 2027

ITALY
Table 115: Italy Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 116: Italy Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 117: Italy 15-Year Perspective for Gene Delivery Systems
by Delivery - Percentage Breakdown of Value Sales for Viral
Gene Delivery and Non-viral Gene Delivery for the Years 2012,
2020 & 2027

Table 118: Italy Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 119: Italy Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 120: Italy 15-Year Perspective for Gene Delivery Systems
by Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 121: Italy Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 122: Italy Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 123: Italy 15-Year Perspective for Gene Delivery Systems
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectable, Inhalation, Transdermal, Ocular,
Nasal and Other Route of Administrations for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 124: UK Current & Future Analysis for Gene Delivery
Systems by Delivery - Viral Gene Delivery and Non-viral Gene
Delivery - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 125: UK Historic Review for Gene Delivery Systems by
Delivery - Viral Gene Delivery and Non-viral Gene Delivery
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 126: UK 15-Year Perspective for Gene Delivery Systems by
Delivery - Percentage Breakdown of Value Sales for Viral Gene
Delivery and Non-viral Gene Delivery for the Years 2012, 2020 &
2027

Table 127: UK Current & Future Analysis for Gene Delivery
Systems by Application - Infectious Diseases, Oncology, CVD,
Urology, CNS and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 128: UK Historic Review for Gene Delivery Systems by
Application - Infectious Diseases, Oncology, CVD, Urology, CNS
and Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 129: UK 15-Year Perspective for Gene Delivery Systems by
Application - Percentage Breakdown of Value Sales for
Infectious Diseases, Oncology, CVD, Urology, CNS and Other
Applications for the Years 2012, 2020 & 2027

Table 130: UK Current & Future Analysis for Gene Delivery
Systems by Route Of Administration - Oral, Injectable,
Inhalation, Transdermal, Ocular, Nasal and Other Route of
Administrations - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 131: UK Historic Review for Gene Delivery Systems by
Route Of Administration - Oral, Injectable, Inhalation,
Transdermal, Ocular, Nasal and Other Route of Administrations
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 132: UK 15-Year Perspective for Gene Delivery Systems by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal
and Other Route of Administrations for the Years 2012, 2020 &
2027

REST OF EUROPE
Table 133: Rest of Europe Current & Future Analysis for Gene

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05960944/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Notre objectif est de créer un endroit sûr et engageant pour que les utilisateurs communiquent entre eux en fonction de leurs centres d’intérêt et de leurs passions. Afin d'améliorer l’expérience dans notre communauté, nous suspendons temporairement les commentaires d'articles